Kane Biotech is a biotechnology company that was formed in 2001, and is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. As each solution has been proven via large scale trials the company is now focused on commercializing each product within defined consumer verticals. Whether you are a direct consumer, veterinarian or dermatologist, Kane Biotech has a tried and tested solution; from our Animal Health products such as bluestem™ oral care to our first Human Health products such as DermaKB™ skin care. Kane Biotech’s commercialization vehicles will provide capital, at attractive valuations, that is non-dilutive to the company. This capital will accelerate our continued product research and development for the future whilst allowing our commercialization beyond North America. Kane has a portfolio of biotechnologies, intellectual trade secrets, and products developed by their own biofilm research teams as well as technologies procured from other leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
